ClinicalTrials.govpublic full text
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
hormone-sensitive, her-2 negative metastatic breast cancer, medi-573, breast cancer, metastatic, aromatase inhibitor, anti-igf, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 805343
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.